OIPE JC101 JUN 01 2004 PATENT & TRADEMARK OFFICE

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/806,295	Confirmation No.: Unassigned
Applicant:	LaColla *et al.*	
Filed:	March 22, 2004	
TC/A.AU.:	Unassigned	
Examiner:	Unassigned	
Docket No.:	06171.105033 IDX 1008 DIV	
Customer No.:	20786	
Title:	Phenylindoles for the Treatment of HIV	

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Transmittal of Information Disclosure Statement

Sir:

The citation of information on the attached Form PTO/SB/08A is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of references AL, AN, and AO are enclosed; copies of the remaining references were cited in the parent application 10/122,252, filed on April 11, 2002, which issued as 6,710,068 on March 23, 2004. The Examiner's attention is also drawn to copending application U.S.S.N. 10/637,949 filed on August 7, 2003. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Because this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits, the Applicants do not believe that any additional fees are due; however, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles
Reg. No. 33,052

Dated May 28, 2004
King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 28, 2004.

Jennifer A. Williams

3495849

OIPE
JUN 0 1 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2

Complete if Known	
Application Number	10/806,295
Filing Date	March 22, 2004
First Named Inventor	LaColla, *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105033 IDX 1008 DIV

3463446_2.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,866,084	A	Gunasekera *et al.*	09-12-1989	
	AB	5,124,327	A	Greenlee *et al.*	06-23-1992	
	AC	5,489,685	A	Houpis *et al.*	02-06-1996	
	AD	5,527,819	A	Williams *et al.*	06-18-1996	
	AE	5,830,894	A	Pevear *et al.*	11-03-1998	
	AF	5,852,011	A	Matsunaga *et al.*	12-22-1998	
	AG	5,929,114	A	Domagala *et al.*	07-27-1999	
	AH	5,935,982	A	Dykstra *et al.*	08-10-1999	
	AI	5,945,440	A	Kleinschroth *et al.*	08-31-1999	
	AJ	5,981,525	A	Farina *et al.*	11-09-1999	
	AK	6,025,390	A	Farina *et al.*	02-15-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	Foreign Patent Document Office [3]	Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AL	EP	0,530,907	A1	Merck & Co.	03-10-1993		
	AM	WO	94/19321	A1	Merck & Co.; Theoharides	09-01-1994		
	AN	WO	02/083126	A1	Idenix; Univ. Degli Studi di Cagliari	10-24-2002		
	AO	WO	04/014364	A1	Idenix	02-19-2004		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	AP	BALANI, S.K., *et al.*, "Biotransformation of 5-chloro-3-phenylthioindole-2-carboxamide (L-734,005) in rhesus monkeys and rat liver microsomes to a potent HIV-1 reverse transcriptase inhibitor," *Drug Metab. Dispso.*, 21(4):598-604 (July-August 1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC761 JUN 0 1 2004 PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2

Complete if Known	
Application Number	10/806,295
Filing Date	March 22, 2004
First Named Inventor	LaColla, *et al.*
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105033 IDX 1008 DIV

3463446_2.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	AQ	CLAUSON-KAAS, N., *et al.*, "Preparation of *Cis* and *Trans* 2,5-Dimethoxy-2-(acetamidomethyl)-2,5-dihydrofuran, of *Cis* and *Trans* 2,5-Dimethoxy-2-(acetamidomethyl)-tetrahydrofuran and of 1-Phenyl-2-(acetamidomethyl)pyrrole," *Acta Chem. Scand.*, 6:667-670 (1952).	
	BA	ELMING, N., *et al.*,"The preparation of pyrroles from furans,"*Acta Chem. Scand.*, 6:867-874 (1952).	
	BB	GAGLIARDI, S., *et al.*, "5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity," *J. Med. Chem.*, 41(10):1568-1573 (May 7, 1998).	
	BC	PAUWELS, R., *et al.*, "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives," *Nature*, 343(6257):470-474 (February 1, 1990).	
	BD	PAUWELS, R., *et al.*, "Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase," *Proc. Natl. Acad. Sci. USA*, 90(5):1711-1715 (March 1, 1993).	
	BE	PHILLIPS, R.R., "The Japp-Klingemann Reaction," *Org. Reactions*, 10:143-178 (1959).	
	BF	ROMERO, D.L., *et al.*, "Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate," *J. Med. Chem.*, 36(10):1505-1508 (May 14, 1993).	
	BG	WILLIAMS, T.M., *et al.*, "5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase, *J. Med. Chem.*, 36(9):1291-1294 (April 30, 1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.